Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand

Annals of Clinical Biochemistry

Volumn 49, Issue 3, 2012, Pages 242-256

  Tate, Jillian ^a   Caldwell, Grahame ^b   Daly, James ^c   Gillis, David ^a   Jenkins, Margaret ^d   Jovanovich, Sue ^e   Martin, Helen ^f   Steele, Richard ^g   Wienholt, Louise ^h   Mollee, Peter ⁱ  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b DOUGLASS HANLY MOIR PATHOLOGY   (Australia)

^c ROYAL HOBART HOSPITAL   (Australia)

^d AUSTIN HOSPITAL   (Australia)

^e FLINDERS MEDICAL CENTRE   (Australia)

^f Healthscope Pathology   (Australia)

^g WELLINGTON HOSPITAL   (New Zealand)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁱ PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; IMMUNOGLOBULIN G; PARAPROTEIN; PLASMA PROTEIN; SERUM ALBUMIN;

AGAR GEL ELECTROPHORESIS; ARTICLE; AUSTRALIA; CAPILLARY ZONE ELECTROPHORESIS; CLINICAL LABORATORY; HUMAN; ISOELECTRIC FOCUSING; LIMIT OF DETECTION; NEW ZEALAND; PATHOLOGIST; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ELECTROPHORESIS; PROTEIN URINE LEVEL; SCIENTIST; SERUM PROTEIN ELECTROPHORESIS; STEM CELL TRANSPLANTATION; URINE PROTEIN ELECTROPHORESIS;

AUSTRALIA; BLOOD PROTEINS; DATA COLLECTION; ELECTROPHORESIS; HUMANS; IMMUNOGLOBULINS; LABORATORIES; MEDICAL LABORATORY PERSONNEL; NEW ZEALAND; PARAPROTEINS; RESEARCH DESIGN; URINE;

EID: 84861503607     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2011.011158     Document Type: Article

References (62)

1. Kyle RA, Child JA, Anderson K, et al., on behalf of the International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57
2. Anderson KC, Alsina M, Bensinger W, et al. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw 2009;7:908-42
3. Smith A, Behrens J, Drayson M, et al., on behalf of the Guidelines Working Group of the UK Myeloma Forum of the British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol 2001;115:522-40
4. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132:410-51
5. Keren DF, Alexanian R, Goeken JA, Gorevic PD, Kyle RA, Tomar RH. Guidelines for clinical and laboratory evaluation of patients with monoclonal gammopathies. Arch Pathol Lab Med 1999;123:106-7
6. Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4:379-98
7. Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009;147:22-42
8. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9
9. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23
10. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. New Engl J Med 2003;348:2609-17
11. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73
12. Harousseau JL, Avet-Loiseau H, Attal M, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials. J Clin Oncol 2009;27:5720-6
13. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139-46
14. Hoering A, Crowley J, Shaughnessy JD Jr, et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood 2009;114:1299-305
15. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006;6:380-3
16. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-28
17. Dimopoulos M, Kyle R, Fermand J-P, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117:4701-5
18. Jenkins MA. Serum and urine electrophoresis for detection and identification of monoclonal proteins. Clin Biochem Rev 2009;30:119-22
19. Tate JR, Mollee P, Gill D. The reporting of serum protein electrophoresis to clinicians. Clin Chim Acta 2005;358:204-5
20. Plebani M. What information on quality specifications should be communicated to clinicians, and how? Clin Chim Acta 2004;346:25-35
21. Inman Z, Martin H, Chubb SP. Reporting of quantitative protein electrophoresis in Australia and New Zealand: a call for standardisation. Clin Biochem Rev 2009;30:141-51
22. Cornell FN. Isoelectric focusing, blotting and probing methods for detection and identification of monoclonal proteins. Clin Biochem Rev 2009;30:123-30
23. Hall SL, Tate J, Gill D, Mollee P. Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. Clin Biochem Rev 2009;30:113-8
24. Hayden K, van Heyningen C. Measurement of total protein is a useful inclusion in liver function test profiles. Clin Chem 2001;47:793-4
25. Beetham R, Howie N, Soutar R. Can opportunistic case-finding of paraproteins be clinically justified? Ann Clin Biochem 2005;42:245-53
26. Gustafsson JE. Improved specificity of serum albumin determination and estimation of 'acute phase reactants' by use of the bromcresol green reaction. Clin Chem 1976;22:616-22
27. Pinnell AE, Northam BE. New automated dye-binding method for serum albumin determination with bromcresol purple. Clin Chem 1978;24:80-6
28. Duggan J, Duggan PF. Albumin by bromcresol green - a case of laboratory conservatism. Clin Chem 1982;28:1407-8
29. Martin H, Sonza B. Comparison of albumin methods. Clin Biochem Rev 2009;30:S24
30. Duly EB, Grimason S, Grimason P, Barnes G, Trinick TR. Measurement of serum albumin by capillary zone electrophoresis, bromocresol green, bromocresol purple, and immunoassay methods. J Clin Pathol 2003;56:780-1
31. Mussap M, Pietrogrande F, Ponchia S, Stefani PM, Sartori R, Plebani M. Measurement of serum monoclonal components: comparison between densitometry and capillary zone electrophoresis. Clin Chem Lab Med 2006;44:609-11
32. Bergon E, Miranda I, Miravalles E. Linearity and detection limit in the measurement of serum M-protein with the capillary zone electrophoresis system Capillarys. Clin Chem Lab Med 2005;43:721-3
33. Riches PG, Sheldon J, Smith AM, Hobbs JR. Overestimation of monoclonal immunoglobulin by immunochemical methods. Ann Clin Biochem 1991;28(Pt 3):253-9
34. Sinclair D, Ballantyne F, Shanley S, Caine E, O'Reilly D, Shenkin A. Estimation of paraproteins by immunoturbidimetry and electrophoresis followed by scanning densitometry. Ann Clin Biochem 1990;27(Pt 4):335-7
35. Murray DL, Ryu E, Snyder MR, Katzmann JA. Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chem 2009;55:1523-9
36. Whicher JT, Warren C, Chambers RE. Immunochemical assays for immunoglobulins. Ann Clin Biochem 1984;21(Pt 2):78-91
37. Bergon E, Miravalles E. Estimation of serum M-protein concentration from polyclonal immunoglobulins: an alternative to serum protein electrophoresis and standard immunochemical procedures. Clin Chem Lab Med 2008;46:1156-62
38. Cornell FN. Densitometry. In: Biegler B, Sykes S, eds. Advanced Electrophoretic Techniques in Clinical Diagnosis Australian Association of Clinical Biochemists Monograph Series. Sydney: AACB, 1989:8-12
39. Lit LCW, Chan MHM, Cheung RCK, et al. Cryoglobulins: identification and clinical significance. Clin Biochem Rev 2000;21:89-92
40. Sargur R, White P, Egner W. Cryoglobulin evaluation: best practice? Ann Clin Biochem 2010;47:8-16
41. Keren DF. Procedures for the evaluation of monoclonal immunoglobulins. Arch Pathol Lab Med 1999;123:126-32
42. Salomo M, Gimsing P, Nielsen LB. Simple method for quantification of Bence Jones proteins. Clin Chem 2002;48:2202-7
43. Graziani M, Merlini G, Petrini C. Guidelines for the analysis of Bence Jones protein. Clin Chem Lab Med 2003;41:338-46
44. Beetham R. Detection of Bence-Jones protein in practice. Ann Clin Biochem 2000;37(Pt 5):563-70
45. Bailey EM, McDermott TJ, Bloch KJ. The urinary light-chain ladder pattern. A product of improved methodology that may complicate the recognition of Bence Jones proteinuria. Arch Pathol Lab Med 1993;117:707-10
46. MacNamara EM, Aguzzi F, Petrini C, et al. Restricted electrophoretic heterogeneity of immunoglobulin light chains in urine: a cause for confusion with Bence Jones protein. Clin Chem 1991;37:1570-4
47. Harrison HH. The 'ladder light chain' or 'pseudo-oligoclonal' pattern in urinary immunofixation electrophoresis (IFE) studies: a distinctive IFE pattern and an explanatory hypothesis relating it to free polyclonal light chains. Clin Chem 1991;37:1559-64
48. Attaelmannan M, Levinson SS. Understanding and identifying monoclonal gammopathies. Clin Chem 2000;46:1230-8
49. Levinson SS, Keren DF. Free light chains of immunoglobulins: clinical laboratory analysis. Clin Chem 1994;40:1869-78
50. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54
51. Tate J, Ferguson W, Callaghan L, Klingberg S, Marshall K, Koerbin G. The lack of harmonisation of methods for total urine protein (TUP) measurement. Clin Biochem Rev 2003;24:S18
52. Jovanovich S, Tate J, Martin H, Wheatland L. Performance of urinary Bence Jones protein measurement in clinical laboratories. Clin Biochem Rev 2010;31:S30
53. Jenkins MA. Urine proteins. In: Palfrey SM, ed. Clinical Applications of Capillary Electrophoresis. New Jersey: Humana Press Inc, 1999:21-8
54. Harle L, Chan C, Bhagavan NV, et al. A healthy young man presenting with multiple rib fractures. Clin Chem 2010;56:1390-2
55. Cornell FN, McLachlan R. Isolectric focusing in the investigation of gammopathies. In: Biegler B, ed. Advanced Electrophoretic Techniques for Protein Investigation in Clinical Diagnosis. Australian Association of Clinical Biochemists Monograph Series. Sydney: AACB, 1985:31-7
56. Fraser CG. Data on components of biological variation. In: Fraser CG, ed. Biological Variation: From Principles to Practice. Washington, DC: AACC Press, 2001:134
57. Fraser CG. Changes in serial measurements. In: Fraser CG, ed. Biological variation: From Principles to Practice. Washington, DC: AACC Press, 2001:67-90
58. Zent CS, Wilson CS, Tricot G, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 1998;91:3518-23
59. Hovenga S, de Wolf JT, Guikema JE, et al. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant 2000;25:723-8
60. Guikema JE, Vellenga E, Veeneman JM, et al. Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation. Br J Haematol 1999;104:748-54
61. Mark T, Jayabalan D, Coleman M, et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol 2008;143:654-60
62. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108:2520-30